Journal
LEUKEMIA & LYMPHOMA
Volume 55, Issue 12, Pages 2830-2834Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.904508
Keywords
Imatinib; copy drug; chronic myeloid leukemia; Glivec/Gleevec; complete hematologic response; Imatib
Categories
Funding
- Novartis Pharmaceuticals Corporation
Ask authors/readers for more resources
Imatinib (Glivec (R)/Gleevec (R)) has shown long-term efficacy and safety in randomized trials. No large-scale studies have prospectively assessed the benefit-risk profile of an imatinib copy drug. We prospectively evaluated the response of patients with chronic myeloid leukemia in chronic phase in one institution. Patients with a complete hematologic response (n = 126) switched from branded imatinib to an imatinib copy drug. Subsequently, all patients switched back to the branded imatinib. Many patients in this study had a loss of hematologic response and tolerability issues with the imatinib copy drug. Hematologic response and tolerability improved upon retreatment with branded Glivec.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available